HZHI Horizon Health International Corporation (CE)

HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS: HZHI) (the Company) Mr. Rocco Di Fruscia, President of Horizon Health International Corp., is pleased to announce the appointment of Dr. Max Arella to Chairman of the Board of Directors of the Company.

Dr. Arella has more than 30 years experience diversified in sectors of academic research, scientific consultation and drug-development with small and large pharmaceutical companies. He has been instrumental to provide HZHI with exciting and high-development potential of Drug Delivery technologies that will represent the core of the company in years to come.

For the past twenty five years, Dr. Arella has acted as a private consultant advising clients and businesses with technological and scientific development, innovative technology transfer and commercial development from University bench top to commercial developments.

From 1993 to 1998, Dr. Arella was elected twice as chairman of the Virology Research Center of the Armand-Frappier Institute/University of Quebec (the "IAF") during which he held the responsibility of managing both the research and the teaching programs (M.Sc. and Ph. D). From 1984 to 1993 Dr. Arella was scholar, assistant professor and professor of Virology at IAF as well as adjunct professor at the School of Graduate Studies of the University of Montreal. He also served as president of the professor association from 1989 to 1992.His academic research is mainly based in the fields of molecular biology, fundamental aspects and applications of the double-stranded RNA virus, as well as amplification systems for the analysis of human and animal viruses, and cancer markers.

Throughout his career, he has written 76 scientific publications, 24 scientific reports for research contracts as well as 28 chapters in books and summaries of techniques. He has been invited to give 52 international conferences, has presented 206 scientific communications and has submitted 3 patents. Mr. Arella is fluent in English, French and Italian. He is also a member of the board of directors of an OTCBB company (Protokinetix) and served in many advisory boards of public traded companies during the 5 years.

"I am pleased to be appointed to Chairman of the Board of such an exciting company, after years of research on the Lactoferrin product by NRL Pharma Japan we are eager to commercialize the product in North America," says Dr. Arella.

Company's business:

HORIZON's Subsidiary 'New Release Lactoferrin Pharma Canada Inc.' is an emerging specialty pharmaceutical company that is committed to supply its Patented delivery systems of enteric lactoferrin, and "PEG-lactoferrin". We have already introduced enteric lactoferrin products in the market as a supplemental food and have also undertaken projects to further study these products and increase their pharmaceutical applications. Since 2008, the company's proprietary enteric lactoferrin has already earned top market share amongst all lactoferrin-containing products.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.

Contacts: Horizon Health International Corp. Rocco Di Fruscia President & CEO 514 586 3799 horizonhealth@shaw.ca www.horizonhealthinternational.com